首页 | 本学科首页   官方微博 | 高级检索  
     

CD44v6在乳腺浸润性导管癌组织中的表达及其临床意义
引用本文:Lian ZQ,Yang MT,Hou JH,Luo RZ,Wang X,Tang J. CD44v6在乳腺浸润性导管癌组织中的表达及其临床意义[J]. 癌症, 2006, 25(10): 1291-1295
作者姓名:Lian ZQ  Yang MT  Hou JH  Luo RZ  Wang X  Tang J
作者单位:华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心胸科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心胸科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心胸科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心胸科,广东,广州,510060
摘    要:背景与目的:近年研究表明,CD44v6与乳腺癌的发生、侵袭和转移密切相关,但其与乳腺癌预后关系的报道结果并不一致。本研究探讨CD44v6在乳腺癌和乳腺癌旁非癌组织中的表达及其与乳腺癌临床病理因素的关系以及对乳腺癌患者预后的预测意义。方法:采用免疫组织化学SP法检测84例乳腺浸润性导管癌和20例癌旁非癌乳腺组织中CD44v6的表达。采用SPSS10.0软件统计分析CD44v6表达与各病理因素的关系,采用Cox比例风险模型分析影响预后的因素。结果:CD44v6在乳腺浸润性导管癌上皮细胞的表达(78.6%)明显高于癌旁非癌乳腺组织上皮(5.0%),差异有显著性(P<0.05);CD44v6的表达与乳腺癌的TNM分期、肿瘤大小、淋巴结转移状况密切相关;中位随访时间为60个月,CD44v6阴性组的总体生存情况优于CD44v6阳性组,有显著性差异(P<0.05),而且随着CD44v6表达的增强,总体生存曲线有逐渐下降的趋势。Cox比例风险模型多因素的预后分析结果显示,ER、TNM分期、CD44v6均是影响预后的独立因素(P<0.05)。结论:CD44v6在乳腺癌组织中的表达明显升高;CD44v6的表达与乳腺癌患者的TNM分期、肿瘤大小、淋巴结转移呈正相关;CD44v6表达升高可作为预测乳腺癌预后的独立指标之一。

关 键 词:乳腺肿瘤  CD44v6  免疫组化  预后
文章编号:1000-467X(2006)10-1291-05
收稿时间:2005-12-20
修稿时间:2006-01-18

Expression and clinical significance of adhesive molecule CD44v6 in breast invasive ductal carcinoma
Lian Zhen-Qiang,Yang Ming-Tian,Hou Jing-Hui,Luo Rong-Zhen,Wang Xi,Tang Jun. Expression and clinical significance of adhesive molecule CD44v6 in breast invasive ductal carcinoma[J]. Chinese journal of cancer, 2006, 25(10): 1291-1295
Authors:Lian Zhen-Qiang  Yang Ming-Tian  Hou Jing-Hui  Luo Rong-Zhen  Wang Xi  Tang Jun
Affiliation:1. State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China 2. Department of Thoracic Surgery, Cancer Center, Sun Yet-sen University, Guangzhou, Guangdong , 510060, P. R. China 3. Department of Pathology, Cancer Center, Sun Yet-sen University, Guangzhou , Guangdong , 510060, P. R. China
Abstract:BACKGROUND & OBJECTIVE: Many researches suggest that CD44v6 is associated with the occurrence, invasion, and metastasis of breast cancer. However the reports about the relationship between CD44v6 expression and the prognosis of breast cancer are conflicting. This study was to investigate the expression of CD44v6 and its correlation to clinicopathologic characteristics and prognosis of breast cancer. METHODS: CD44v6 expression in 84 specimens of breast cancer and 20 specimens of para-tumor breast tissues was detected by SP immunohistochemistry. COX proportional hazards model was used to analyze the prognosis. RESULTS: The positive rate of CD44v6 in the epithelial cells of breast cancer was significantly higher than that in para-tumor breast tissues (78.6% vs. 5.0%, P<0.05). The expression of CD44v6 was closely correlated to TNM stage, tumor size, and lymph node metastasis (P<0.05). The median follow-up period was 60 months. The overall survival rate was significantly higher in CD44v6-negative group than in CD44v6-positive group (P<0.05). The survival curve had a tendency to decline with the stronger expression of CD44v6. Cox model revealed that ER, TNM stage, and CD44v6 were independent prognostic factors of breast cancer. CONCLUSIONS: CD44v6 is highly expressed in breast cancer, and positively correlated to TNM stage, tumor size, and lymph node metastasis. CD44v6 is an independent prognostic factor of breast cancer.
Keywords:CD44v6
本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号